Debate resolved: There are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes

Journal of Psychopharmacology

Volumn 12, Issue 3 SUPPL. B, 1998, Pages

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Kansas School of Medicine Wichita Psychiatric Research Institute   (United States)

Author keywords

Citalopram; Cytochrome P450 enzymes; Fluoxetine; Fluvoxamine; Paroxetine; Serotonin selective reuptake inhibitors; Sertraline

Indexed keywords

CITALOPRAM; CYTOCHROME P450; DEXTROMETHORPHAN; FLUOXETINE; FLUVOXAMINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ARTICLE; CLINICAL TRIAL; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL;

EID: 0031733037     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881198012003051     Document Type: Article

References (59)

1. Albers L J, Reist C, Helmeste D, Vu R, Tang SW (1996) Paroxetine shifts imipramine metabolism. Psychiatry Res 59: 189-196.
2. Alderman J, Preskorn S, Greenblatt D, et al. (1997) Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 17(4): 284-291.
3. Alfaro C, Ereshefsky L, Lam YWF (1997) Relationship of venlafaxine, fluoxetine, sertraline, and paroxetine plasma concentration with CYP2D6 inhibition. Paper presentated at the 37th Annual Meeting of NCDEU, Boca Raton.
4. Amchin J, Albano D, Troy S, et al. (1996) Venlafaxine's low drug interaction potential based on cytochrome P450: in vivo evidence confirming in vitro data of low CYP2D6 and no CYP3A4 inhibition. Paper presented at the Annual Meeting of Association of Medicine and Psychiatry, San Antonio.
5. Baumann P, Bertschy G (1993) Pharmacodynamic and pharmacokinetic interactions of selective serotonin re-uptake inhibiting antidepressants (SSRIs) with, other psychotropic drugs. Nord J Psychiatry 47 (Suppl. 30): 13-19.
6. Belpaire FM, Wijnant A, Bogaert M, Rasmussen B, Brosen K (1998) Inhibition of the oxidative metabolism of metoprolol by the selective serotonin reuptake inhibitors in human liver microsomes. Poster presentation at Belgian Society of Fundamental and Clinical Psychology and Pharmacology Meeting, 1996.
7. Bergstrom R, Goldberg M, Cerimele B, Hatcher B (1997) Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clin Pharmacol Ther 62: 643-651.
8. Bergstrom RF, Peyton A L, Lemberger L (1992) Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 51: 239-248.
9. Brosen K (1996) Are pharmacokinetic drug interactions with the SSRIs an issue? Int Clin Psychopharmacol 11: 23-27.
10. Brosen K, Hansen JG, Neilsen KK, Sindrup SH, Gram LF (1993) Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 44: 349-355.
11. Centorrino F, Baidessarini R, Frankenburg F, Kando J, Volpicelli S, Flood J (1996) Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 153: 820-822.
12. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE (1992) The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34: 262-265.
13. Cupp MJ, Tracy TS (1998) Cytochrome P450: new nomenclature and clinical implications [abstract]. Am Fam Physician 57: 107-116.
14. Dahl M, Llerena A, Bondesson U, Lindstrom L, Bertilsson L (1994) Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol 37: 71-74.
15. Data from IMS American National Disease and Therapeutic Index (1997) [abstract].
16. DeVane C L (1996) Dr DeVane replies. J Clin Psychiatry 57: 225-227.
17. Ereshefsky L (1996) Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 16: 37-50.
18. Ereshefsky L, Amchin J, Zarycranski W, Heath G (1996) Relationship of plasma concentrations of fluoxetine and vealafaxine with effects on CYP2D6 in vivo. Poster presentation at the 36th Annual Meeting of New Clinical Drug Evaluation Unit, May 28-31, 1996; Boca Raton, Florida.
19. Flockhart D (1996) Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic? J Clin Psychopharmacol 16: 101-103.
20. Gram LF, Hansen MGJ, Sindrup SH, et al. (1993) Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit 15: 18-24.
21. Harvey A, Preskorn S (1996) Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I and Part II. J Clin Psychopharmacol 16: 273-285 and 345-355.
22. Jann M, Carson S, Grimsley S, Erikson S, Kumar A, Carter J (1995) Effects of sertraline (SER) upon imipramine (IMI) pharmacodynamics [abstract]. Clin Pharmacol Ther 57: 207.
23. Jeppesen U, Gram L F, Vistisen K, Loft S, Poulsen HE, Brosen K (1996) Dose-dependent inhibition of CYP1A2, CYP2C19, and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51: 73-78.
24. Jerling M, Lindstrom L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16: 368-374.
25. Joblin M, Ghose K (1994) Possible interaction of sertraline with carbamazepine. N Z Med J 107: 43.
26. Kurtz D, Bergstrom R, Goldberg M, Cerimale B (1994) Drug interaction between sertraline and desipramine or imipramine [abstract]. J Clin Pharmacol 34: 10-30.
27. Kurtz D, Bergstrom R, Goldberg M, Cerimele B (1997) The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Phamacol Therap 62: 145-156.
28. Lam YWF, Ereshefsky L, Riesenman C, Simpson J (1996) In vivo comparison of CYP2D6 inhibition among SSRIs: implication for drug interactions. Poster presentation at the Annual Meeting of the American Psychiatric Association, May 7, 1996; New York, NY.
29. Maes M, Westenberg H, Vandoolaeghe E, Demedts P, Wauters A, Neels H, Meltzer H (1997) Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of metachlorophenylpiperazine. J Clin Psychopharmacol 17: 358-364.
30. Martin D, Zussman B, Everitt D, Benincosa L, Etheredge R, Jorkasky D (1997) Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. J Clin Psychopharmacol 17; 451-459.
31. Nemeroff C, DeVane C, Pollock B (1996) Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153: 311-320.
32. Otton SV, Ball SE, Cheung SW, Inaba T, Sellers EM (1994) Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine (VF) and other 5HT uptake inhibitors [abstract]. Clin Pharmacol Ther 55: 141.
33. Otton S V, Wu D, Joffe RT, Cheung SW, Sellers E M (1993) Inhibition byfluoxetine of cytochrome P450 2D6 activity 53: 401-409.
34. Ozdemir V, Naranjo CA, Herrmann N, Shulman RW, Sellers EM, Kalow W (1997) Sertraline effects on CYP1A2 and CYP2D6 isozyme activities in younger adults and the elderly. J Clin Psychopharmacol 18: 55-61.
35. Pirmohamed M, Williams D, Madden S, Templeton E, Park B (1995) Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 272: 984-990.
36. Preskorn S (1993) Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 94 (Suppl. 5A): 2S-12S.
37. Preskorn S (1995) Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 56: 12-21.
38. Preskorn S (1997a) I don't see 'em. J Prac Psych Behav Health 3: 302-307.
39. Preskorn S (1997b) The clinical relevant pharmacology of serotonin selective reuptake inhibitors. Clin Pharmacokinet 32: 1-21.
40. Preskorn S (1997c) Let the data speak to you. J Prac Psych Behav Health 3: 45-48.
41. Preskorn S, Alderman J, Chung M, HarrisonW, Messig M, Harris S (1994) Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 14: 90-98.
42. Preskorn S, Alderman J, Greenblatt D, Horst W D (1997) Sertraline does not inhibit cytochrome (CYP) 3A-mediated drug metabolism in vivo. Psychopharmacol Bull 33: 659-665.
43. Preskorn S, Beber JH, Faul JC, Hirschfeld RMA (1990) Serious adverse effects of combining fluoxetine and tricyclic antidepressants. Am J Psychiatry 147: 532.
44. Preskorn S, Harvey A (1998) Cytochrome P450 enzymes and psychopharmacology. In Watson S, ed. Psychopharmacology: The Fourth Generation of Progress (CD-ROM version). Philadelphia: Raven Press (in press).
45. Preskorn S, Lacey R (1995) Polypharmacy: when is it rational? J Prac Psych Behav Health 1: 92-98.
46. Preskorn S, Lane R (1995) Sertraline 50 mg daily: the optimal dose in the treatment of depression. Int J Clin Pharmacol 10: 129-141.
47. Preskorn S, Nemeroff C (1997) Debate: are CYP450 drug interactions really important, or is it all just marketing hype? [abstract]. 8(2): 57-63.
48. Richelson E (1997) Pharmacokinetic drug interactions of new-age antidepressants: a review for the practitioner on effects on the metabolism of other drugs. Mayo Clin Proc 72(9): 835-847.
49. Schatzberg A, Kaplan E, Richelson E, Strouse T (1995) The cytochrome P450 system and drug/drug interactions. J Clin Psychiatry 56(11): 1-10.
50. Shad MU, Preskorn S (1999) Antidepressants. In Levy RH, Thummer K, Troger B, Hansten P, Eichelbaum M, eds. Metabolic drug interactions. Lippincott-Raven Publishers, Philadelphia (in press).
51. Shader RI, von Moltke LL, Schmider J, Harmatz JS, Greenblatt D J (1996) The clinician and drug interactions - an update [editorial]. J Clin Psychopharmacol 16: 197-201.
52. Skjelbo E, Brosen K (1992) Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 34: 256-261.
53. Solai LK, Mulsant BH, Pollock BG, Sweet RA, Rosen J, Reynolds CF III (1997) Effect of sertraline on plasma nortriptyline levels in depressed elderly. J Clin Psychiatry 58: 440-443.
54. Spina E, Pollicino AM, Avenoso A, Campo G M, Perucca E, Caputi AP (1993) Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 15: 243-246.
55. Sproule B, Otton S V, Cheung S W, Zhong X H, Romach M K, Sellers E M (1997) CYP2D6 inhibition in patients treated with sertraline. J Clin Psychopharmacol 17: 102-106.
56. von Moltke LL, Greenblatt DJ, Court MH, Duan S X, Harmatz JS, Shader RI (1995) Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 15: 125-131.
57. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright C E, Shader RI (1996) Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 16: 104-112.
58. Young C (1997) A case of neuroleptic malignant syndrome and serotonin disturbance [letter to the editor]. J Clin Psychopharmacol 17: 65-66.
59. Zussman B, Davie C, Fowles S, et al. (1995) Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. BrJ Clin Pharmacol 39: 550-551.